Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Main Inclusion Criteria: * Treated with a stable dose of metformin or sulfonylurea for at least 3 months prior to screening. * HbA1c between 7.1% and 11.0%, inclusive. * Insulin therapy should be the next appropriate step of diabetes treatment. * Body Mass Index (BMI) \>25 kg/m2 and \<40 kg/m2. Main Exclusion Criteria: * Patient previously in a study involving exenatide or glucagon-like peptide-1 analogs. * Treated with insulin, thiazolidinediones, alpha-glucosidase inhibitors, or meglitinides within 3 months prior to screening.